Principal Financial Group
VYNE icon

Principal Financial Group’s VYNE Therapeutics VYNE Stock Holding History

Principal Financial Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-567
Closed -$14K – 2653
2021
Q3 		$14K Sell
567
-91
-14% -$3.53K ﹤0.01% 2573
2021
Q2 		$42K Buy
+658
New +$52.1K ﹤0.01% 2582
2020
Q4 		– Sell
-157
Closed -$19K – 2462
2020
Q3 		$19K Buy
+157
New +$18.3K ﹤0.01% 2315

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Principal Financial Group's VYNE Position: Q4 2021 in Review

Principal Financial Group sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 567 shares — an estimated $14K sold.

Principal Financial Group first reported a position in VYNE in Q3 2020 and held it in 3 quarters. The position peaked at $42K in Q2 2021. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

  • Principal Financial Group reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 567 VYNE Therapeutics shares in Q4 2021, an estimated $14K.
  • Principal Financial Group first reported a position in VYNE Therapeutics in Q3 2020 and held it in 3 quarters.
  • Principal Financial Group's VYNE Therapeutics position peaked at $42K in Q2 2021.
  • 54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.